Rabbit monoclonal antibodies permit higher working dilutions (5 - 10X on average) and can be used with various tissue fixations, such as FFPE at minimal level of pretreatment. RabMAb primary antibodies are always tested on human lymphoid/lymphoma tissue micro-array (TMA) constructed with FFPE tissues for immunohistochemical staining. Additionally, when used along with a mouse monoclonal, one can perform dual staining with two monoclonal antibodies for high quality double staining on the same tissue sample.
Our Custom Services team also has a demonstrated record of success developing custom RabMAb primary antibodies with increased sensitivity making them “best in class” for IHC.
“The rabbit monoclonal antibody against Ercc1 (ab129267) worked beautifully on the first try of our IHC experiments. Our lab works with mice that have either knocked-out Ercc1 or a lower expression of Ercc1 (25% expression). There is a clear difference between the expression of a WT, KO, and lower expression Ercc1 in all tissues (picture of testis shown).”
Researcher, The Scripps Research Institute
A comparison of a HER2 / ErbB2 RabMAb primary antibody with leading commercially available HER2 / ErbB2 rabbit polyclonal (vendor A) and mouse monoclonal (vendor B) antibodies on FFPE human breast carcinoma tissue. Our recommended IHC protocol and dilution factor were used for each case, the antibody concentrations used are listed below the images for each stain.
HER2 RabMAb primary antibody [3 ng/mL]
Rabbit polyclonal antibody (Vendor A) [20 ng/mL]
Mouse monoclonal antibody (Vendor B) [30ng/mL]
CK8 and Ki67
IHC on human urinary bladder cancer tissue using anti-CK8 RabMAb primary antibody (ab53280) with Fast Red and anti-Ki67 Mouse MAb with DAB.
IHC on human breast cancer tissue using anti-HER2 / ErbB2 RabMAb primary antibody (ab134182) with Fast Red and anti-ER Alpha Mouse MAb with DAB.
IHC on human prostate cancer tissue using anti-AIF RabMAb primary antibody (ab32516) with Fast Red and anti-p53 Mouse MAb with DAB.
The data below from the lab of Dr. Schulz, Institute of Pharmacology and Toxicology, Jena University Hospital demonstrates the detection of Somatostatin Receptor 1 (a GPCR) in cancerous tissues with a custom RabMAb primary antibody. This Somatostatin Receptor 1 RabMAb primary antibody [UMB7] (ab137083), which is specific for sst1, was developed using our RabMAb technology.
+ Peptide refers to staining in the presence of the immunizing peptide, a measure of specificity.
Reprinted from Regulatory Peptides,183, Lupp A, Nagel F, Schulz S., Reevaluation of sst1 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-7., 1-6., Copyright (2013), with permission from Elsevier